Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 8/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 3/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24703969 | 0.89 | KDM4E (0.34) | MMP3MMP9FOLH1SIRT6SIRT1 | |
| SCHEMBL24678191 | 0.89 | KDM4E (0.34) | MMP3MMP9FOLH1SIRT6SIRT1 | |
| SCHEMBL22912627 | 0.87 | NOD1 (0.44) | NOD1 | |
| SCHEMBL20016488 | 0.87 | OPRK1 (0.33) | FURINSIRT6SIRT1OPRK1ITGB3 | |
| SCHEMBL24239548 | 0.87 | OPRK1 (0.33) | FURINSIRT6SIRT1OPRK1ITGB3 | |
| SCHEMBL19062769 | 0.87 | OPRK1 (0.33) | FURINSIRT6SIRT1OPRK1ITGB3 | |
| SCHEMBL22692642 | 0.86 | NOD1 (0.46) | NOD1 | |
| SCHEMBL18929779 | 0.85 | OPRK1 (0.30) | MMP3MMP9OPRK1 | |
| SCHEMBL21154982 | 0.82 | ITGB3 (0.32) | OPRK1ITGB3ITGA2B | |
| SCHEMBL21902132 | 0.82 | OPRK1 (0.31) | OPRK1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-9932581-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | MMP3 3123/4885MMP9 3846/4885FOLH1 422/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | MMP3 3123/4885MMP9 3846/4885FOLH1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.